Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-TIL and Tislelizumab in Advanced Malignant Melanoma
NCT04924413Phase 2Terminated
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of L-TIL cells in Malignant Melanoma (MM). Primary endpoints: Objective Response Rate at 16 weeks and Duration of Response at 2 years. Started Jul 2021; status: terminated.
02
Drugs
L-TIL cells
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04924413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924413.